Involvement of heparanase in atherosclerosis and other vessel wall pathologies

Matrix Biology

Volumn 32, Issue 5, 2013, Pages 241-251

  Vlodavsky, Israel ^a   Blich, Miry ^b   Li, Jin Ping ^c   Sanderson, Ralph D ^d   Ilan, Neta ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Department of Cardiology ^*  (Israel)

^c UPPSALA UNIVERSITY   (Sweden)

^d University of Alabama at Birmingham   (United States)

Author keywords

Atherosclerosis; Colitis; Diabetic nephropathy; Extracellular matrix; Heparan sulfate; Heparanase; Inflammation; Macrophages; Stenosis; Thrombosis; Vulnerable plaque

Indexed keywords

CD163 ANTIGEN; COLLAGEN; CREATININE; CYTOKINE; ELASTIN; FIBRIN; GELATINASE A; GELATINASE B; HEPARANASE; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MATRIX METALLOPROTEINASE 14; MONOCYTE CHEMOTACTIC PROTEIN 1; PI 88; PROTEOHEPARAN SULFATE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACUTE HEART INFARCTION; ARTERY COMPLIANCE; ATHEROSCLEROSIS; CANCER GROWTH; CARDIOVASCULAR FUNCTION; CAROTID ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE COURSE; ENDARTERECTOMY; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLOMERULUS FILTRATION RATE; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; MACROPHAGE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STENOSIS; STENT; STENT THROMBOSIS; THROMBOSIS;

ANIMALS; ATHEROSCLEROSIS; CAROTID ARTERIES; EXTRACELLULAR MATRIX; GLUCURONIDASE; HEPARITIN SULFATE; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; NEOPLASMS; PLAQUE, ATHEROSCLEROTIC; THROMBOSIS;

MAMMALIA;

EID: 84879602165     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2013.03.002     Document Type: Review

References (103)

1. Aalkjaer C., Boedtkjer D.B. Getting neointimal: the emergence of heparanase into the vascular matrix. Circ. Res. 2009, 104:277-279.
2. Abboud-Jarrous G., Atzmon R., Peretz T., Palermo C., Gadea B.B., Joyce J.A., Vlodavsky I. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J. Biol. Chem. 2008, 283:18167-18176.
3. Arvatz G., Shafat I., Levy-Adam F., Ilan N., Vlodavsky I. The heparanase system and tumor metastasis: is heparanase the seed and soil?. Cancer Metastasis Rev. 2011, 30:253-268.
4. Baker A.B., Groothuis A., Jonas M., Ettenson D.S., Shazly T., Zcharia E., Vlodavsky I., Seifert P., Edelman E.R. Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circ. Res. 2009, 104:380-387.
5. Baker A.B., Chatzizisis Y.S., Beigel R., Jonas M., Stone B.V., Coskun A.U., Maynard C., Rogers C., Koskinas K.C., Feldman C.L., Stone P.H., Edelman E.R. Regulation of heparanase expression in coronary artery disease in diabetic, hyperlipidemic swine. Atherosclerosis 2010, 213:436-442.
6. Baker A.B., Gibson W.J., Kolachalama V.B., Golomb M., Indolfi L., Spruell C., Zcharia E., Vlodavsky I., Edelman E.R. Heparanase regulates thrombosis in vascular injury and stentinduced flow disturbance. J. Am. Coll. Cardiol. 2012, 59:1551-1560.
7. Barash U., Cohen-Kaplan V., Dowek I., Sanderson R.D., Ilan N., Vlodavsky I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J. 2010, 277:3890-3903.
8. Bernfield M., Gotte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 1999, 68:729-777.
9. Blich M., Golan A., Arvatz G., Sebbag A., Shafat I., Sabo E., Cohen-Kaplan V., Petcherski S., Avniel-Polak S., Eitan A., Hammerman H., Aronson D., Axelman E., Ilan N., Nussbaum G., Vlodavsky I. Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler. Thromb. Vasc. Biol. 2013, 33:e56-e65.
10. Boquist S., Ruotolo G., Tang R., Bjorkegren J., Bond M.G., de Faire U., Karpe F., Hamsten A. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation 1999, 100:723-728.
11. Brunn G.J., Bungum M.K., Johnson G.B., Platt J.L. Conditional signaling by Toll-like receptor 4. FASEB J. 2005, 19:872-874.
12. Camejo G., Hurt-Camejo E., Wiklund O., Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998, 139:205-222.
13. Casu B., Vlodavsky I., Sanderson R.D. Non-anticoagulant heparins and inhibition of cancer. Pathophysiol. Haemost. Thromb. 2008, 36:195-203.
14. Chen G., Wang D., Vikramadithyan R., Yagyu H., Saxena U., Pillarisetti S., Goldberg I.J. Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry 2004, 43:4971-4977.
15. Cochran S., Li C., Fairweather J.K., Kett W.C., Coombe D.R., Ferro V. Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J. Med. Chem. 2003, 46:4601-4608.
16. Cohen-Kaplan V., Naroditsky I., Zetser A., Ilan N., Vlodavsky I., Doweck I. Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int. J. Cancer 2008, 123:2566-2573.
17. Coombe D.R., Kett W.C. Heparin mimetics. Handb. Exp. Pharmacol. 2012, 207:361-383.
18. Couchman J.R. Transmembrane signaling proteoglycans. Annu. Rev. Cell Dev. Biol. 2010, 26:89-114.
19. Deng Y., Foley E.M., Gonzales J.C., Gordts P.L., Li Y., Esko J.D. Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearance. Hepatology 2012, 55:277-286.
20. Doweck I., Kaplan-Cohen V., Naroditsky I., Sabo E., Ilan N., Vlodavsky I. Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 2006, 8:1055-1061.
21. Dredge K., Hammond E., Handley P., Gonda T.J., Smith M.T., Vincent C., Brandt R., Ferro V., Bytheway I. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br. J. Cancer 2011, 104:635-642.
22. Edelman E.R., Adams D.H., Karnovsky M.J. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:3773-3777.
23. Fitzgerald M., Hayward I.P., Thomas A.C., Campbell G.R., Campbell J.H. Matrix metalloproteinase can facilitate the heparanase-induced promotion of phenotype change in vascular smooth muscle cells. Atherosclerosis 1999, 145:97-106.
24. Fux L., Feibish N., Cohen-Kaplan V., Gingis-Velitski S., Feld S., Geffen C., Vlodavsky I., Ilan N. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res. 2009, 69:1758-1767.
25. Fux L., Ilan N., Sanderson R.D., Vlodavsky I. Heparanase: busy at the cell surface. Trends Biochem. Sci. 2009, 34:511-519.
26. Gil N., Goldberg R., Neuman T., Garsen M., Zcharia E., Rubinstein A., van Kuppevelt T., Meirovitz A., Pisano C., Li J.-P., van der Vlag J., Vlodavsky I., Elkin M. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 2012, 61:208-216.
27. Goldberg R., Meirovitz A., Hirshoren N., Bulvik R., Binder A., Rubinstein A.M., Elkin M. Versatile role of heparanase in inflammation. Matrix Biol. 2013.
28. Hacker U., Nybakken K., Perrimon N. Heparan sulphate proteoglycans: the sweet side of development. Nat. Rev. 2005, 6:530-541.
29. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
30. He Y.Q., Sutcliffe E.L., Bunting K.L., Li J., Goodall K.J., Poon I.K., Hulett M.D., Freeman C., Zafar A., McInnes R.L., Taya T., Parish C.R., Rao S. The endoglycosidase heparanase enters the nucleus of T lymphocytes and modulates H3 methylation at actively transcribed genes via the interplay with key chromatin modifying enzymes. Transcription 2011, 3:130-145.
31. Hermano E., Lerner I., Elkin M. Heparanase enzyme in chronic inflammatory bowel disease and colon cancer. Cell. Mol. Life Sci. 2012, 69:2501-2513.
32. Hulett M.D., Hornby J.R., Ohms S.J., Zuegg J., Freeman C., Gready J.E., Parish C.R. Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 2000, 39:15659-15667.
33. Ilan N., Elkin M., Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int. J. Biochem. Cell Biol. 2006, 38:2018-2039.
34. Iozzo R.V., Sanderson R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell. Mol. Med. 2011, 15:1013-1031.
35. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
36. Khachigian L.M., Parish C.R. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc. Drug Rev. 2004, 22:1-6.
37. Kobayashi M., Naomoto Y., Nobuhisa T., Okawa T., Takaoka M., Shirakawa Y., Yamatsuji T., Matsuoka J., Mizushima T., Matsuura H., Nakajima M., Nakagawa H., Rustgi A., Tanaka N. Heparanase regulates esophageal keratinocyte differentiation through nuclear translocation and heparan sulfate cleavage. Differentiation 2006, 74:235-243.
38. Lerner I., Hermano E., Zcharia E., Rodkin D., Bulvik R., Doviner V., Rubinstein A.M., Ishai-Michaeli R., Atzmon R., Sherman Y., Meirovitz A., Peretz T., Vlodavsky I., Elkin M. Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J. Clin. Invest. 2011, 121:1709-1721.
39. Levy-Adam F., Miao H.Q., Heinrikson R.L., Vlodavsky I., Ilan N. Heterodimer formation is essential for heparanase enzymatic activity. Biochem. Biophys. Res. Commun. 2003, 308:885-891.
40. Levy-Adam F., Feld S., Cohen-Kaplan V., Shteingauz A., Gross M., Arvatz G., Naroditsky I., Ilan N., Doweck I., Vlodavsky I. Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J. Biol. Chem. 2010, 285:28010-28019.
41. Li J.P., Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb. Haemost. 2009, 102:823-828.
42. Li R.W., Freeman C., Yu D., Hindmarsh E.J., Tymms K.E., Parish C.R., Smith P.N. Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis. Arthritis Rheum. 2008, 58:1590-1600.
43. Lindahl U., Li J.P. Interactions between heparan sulfate and proteins-design and functional implications. Int. Rev. Cell Mol. Biol. 2009, 276:105-159.
44. Liu C.J., Lee P.H., Lin D.Y., Wu C.C., Jeng L.B., Lin P.W., Mok K.T., Lee W.C., Yeh H.Z., Ho M.C., Yang S.S., Lee C.C., Yu M.C., Hu R.H., Peng C.Y., Lai K.L., Chang S.S., Chen P.J. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J. Hepatol. 2009, 50:958-968.
45. McKenzie E.A. Heparanase: a target for drug discovery in cancer and inflammation. Br. J. Pharmacol. 2007, 151:1-14.
46. McKenzie E., Tyson K., Stamps A., Smith P., Turner P., Barry R., Hircock M., Patel S., Barry E., Stubberfield C., Terrett J., Page M. Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem. Biophys. Res. Commun. 2000, 276:1170-1177.
47. McKenzie E., Young K., Hircock M., Bennett J., Bhaman M., Felix R., Turner P., Stamps A., McMillan D., Saville G., Ng S., Mason S., Snell D., Schofield D., Gong H., Townsend R., Gallagher J., Page M., Parekh R., Stubberfield C. Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem. J. 2003, 373:423-435.
48. Meirovitz A., Hermano E., Lerner I., Zcharia E., Pisano C., Peretz T., Elkin M. Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res. 2011, 71:2772-2780.
49. Munesue S., Yoshitomi Y., Kusano Y., Koyama Y., Nishiyama A., Nakanishi H., Miyazaki K., Ishimaru T., Miyaura S., Okayama M., Oguri K. A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J. Biol. Chem. 2007, 282:28164-28174.
50. Myler H.A., Lipke E.A., Rice E.E., West J.L. Novel heparanase-inhibiting antibody reduces neointima formation. J. Biochem. 2006, 139:339-345.
51. Nadir Y., Brenner B., Zetser A., Ilan N., Shafat I., Zcharia E., Goldshmidt O., Vlodavsky I. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J. Thromb. Haemost. 2006, 4:2443-2451.
52. Nadir Y., Brenner B., Gingis-Velitski S., Levy-Adam F., Ilan N., Zcharia E., Nadir E., Vlodavsky I. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. Thromb. Haemost. 2008, 99:133-141.
53. Nadir Y., Brenner B., Fux L., Shafat I., Attias J., Vlodavsky I. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. Haematologica 2010, 95:1927-1934.
54. Naggi A., Casu B., Perez M., Torri G., Cassinelli G., Penco S., Pisano C., Giannini G., Ishai-Michaeli R., Vlodavsky I. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J. Biol. Chem. 2005, 280:12103-12113.
55. Ogren S., Lindahl U. Cleavage of macromolecular heparin by an enzyme from mouse mastocytoma. J. Biol. Chem. 1975, 250:2690-2697.
56. Okada Y., Yamada S., Toyoshima M., Dong J., Nakajima M., Sugahara K. Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence. J. Biol. Chem. 2002, 8(277):42488-42495.
57. Osterholm C., Folkersen L., Lengquist M., Ponten F., Renne T., Li J., Hedin U. Increased expression of heparanase in symptomatic carotid atherosclerosis. Atherosclerosis 2013, 226:67-73.
58. Ostrovsky O., Korostishevsky M., Shafat I., Mayorov M., Ilan N., Vlodavsky I., Nagler A. Inverse correlation between HPSE gene single nucleotide polymorphisms and heparanase expression: possibility of multiple levels of heparanase regulation. J. Leukoc. Biol. 2009, 86:445-455.
59. Parish C.R., Freeman C., Hulett M.D. Heparanase: a key enzyme involved in cell invasion. Biochim. Biophys. Acta 2001, 1471:M99-M108.
60. Parish C.R., Freeman C., Ziolkowski A.F., He Y.Q., Sutcliffe E.L., Zafar A., Rao S., Simeonovic C.J. Unexpected new roles for heparanase in type 1 diabetes and immune gene regulation. Matrix Biol. 2013.
61. Peterson S.B., Liu J. Unraveling the specificity of heparanase utilizing synthetic substrates. J. Biol. Chem. 2010, 285:14504-14513.
62. Peterson S., Liu J. Deciphering mode of action of heparanase using structurally defined oligosaccharides. J. Biol. Chem. 2012, 287:34836-34843.
63. Pikas D.S., Li J.-P., Vlodavsky I., Lindahl U. Substrate specificity of heparanases from human hepatoma and platelets. J. Biol. Chem. 1998, 273:18770-18777.
64. Planer D., Metzger S., Zcharia E., Wexler I.D., Vlodavsky I., Chajek-Shaul T. Role of heparanase on hepatic uptake of intestinal derived lipoprotein and fatty streak formation in mice. PLoS One 2011, 6:e18370.
65. Purushothaman A., Chen L., Yang Y., Sanderson R.D. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J. Biol. Chem. 2008, 283:32628-32636.
66. Purushothaman A., Uyama T., Kobayashi F., Yamada S., Sugahara K., Rapraeger A.C., Sanderson R.D. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010, 115:2449-2457.
67. Purushothaman A., Hurst D.R., Pisano C., Mizumoto S., Sugahara K., Sanderson R.D. Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J. Biol. Chem. 2011, 286:30377-30383.
68. Purushothaman A., Babitz S.K., Sanderson R.D. Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma. J. Biol. Chem. 2012, 287:41288-41296.
69. Ramani V.C., Yang Y., Ren Y., Nan L., Sanderson R.D. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J. Biol. Chem. 2011, 286:6490-6499.
70. Ramani V.C., Pruett P.S., Thompson C.A., Delucas L.D., Sanderson R.D. Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. J. Biol. Chem. 2012, 287:9952-9961.
71. Ritchie J.P., Ramani V.C., Ren Y., Naggi A., Torri G., Casu B., Penco S., Pisano C., Carminati P., Tortoreto M., Zunino F., Vlodavsky I., Sanderson R.D., Yang Y. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin. Cancer Res. 2011, 17:1382-1393.
72. Sanderson R.D., Iozzo R.V. Targeting heparanase for cancer therapy at the tumor-matrix interface. Matrix Biol. 2012, 31:283-284.
73. Sanderson R.D., Yang Y., Suva L.J., Kelly T. Heparan sulfate proteoglycans and heparanase-partners in osteolytic tumor growth and metastasis. Matrix Biol. 2004, 23:341-352.
74. Schaefer L., Iozzo R.V. Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr. Opin. Genet. Dev. 2012, 22:56-57.
75. Schmidt E.P., Yang Y., Janssen W.J., Gandjeva A., Perez M.J., Barthel L., Zemans R.L., Bowman J.C., Koyanagi D.E., Yunt Z.X., Smith L.P., Cheng S.S., Overdier K.H., Thompson K.R., Geraci M.W., Douglas I.S., Pearse D.B., Tuder R.M. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat. Med. 2012, 2012. (July 22) http://dx.doi.org/10.1038/nm.2843.
76. Shafat I., Ben-Barak A., Postovsky S., Elhasid R., Ilan N., Vlodavsky I., Ben Arush M.W. Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment. Neoplasia 2007, 9:909-916.
77. Shafat I., Ben-Arush M.W., Issakov J., Meller I., Naroditsky I., Tortoreto M., Cassinelli G., Lanzi C., Pisano C., Ilan N., Vlodavsky I., Zunino F. Pre-clinical and clinical significance of heparanase in Ewing's sarcoma. J. Cell. Mol. Med. 2011, 15:1857-1864.
78. Shafat I., Ilan N., Zoabi S., Vlodavsky I., Nakhoul F. Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels. PLoS One 2011, 6:e17312.
79. Shafat I., Agbaria A., Boaz M., Schwartz D., Baruch R., Nakash R., Ilan N., Vlodavsky I., Weinstein T. Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function. PLoS One 2012, 7:e44076.
80. Tabas I., Williams K.J., Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832-1844.
81. Timpl R., Brown J.C. Supramolecular assembly of basement membranes. Bioessays 1996, 18:123-132.
82. Udo Hacker K.N.a.N.P. Heparan sulphate proteoglycans: the sweet side of development. Nat. Rev. Mol. Cell Biol. 2005, 6:530-541.
83. van den Berg B.M., Spaan J.A., Vink H. Impaired glycocalyx barrier properties contribute to enhanced intimal low-density lipoprotein accumulation at the carotid artery bifurcation in mice. Pflugers Arch. 2009, 457:1199-1206.
84. van den Hoven M.J., Rops A.L., Bakker M.A., Aten J., Rutjes N., Roestenberg P., Goldschmeding R., Zcharia E., Vlodavsky I., van der Vlag J., Berden J.H. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int. 2006, 70:2100-2108.
85. Vikramadithyan R.K., Kako Y., Chen G., Hu Y., Arikawa-Hirasawa E., Yamada Y., Goldberg I.J. Atherosclerosis in perlecan heterozygous mice. J. Lipid Res. 2004, 45:1806-1812.
86. Vlodavsky I., Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 2001, 108:341-347.
87. Vlodavsky I., Bar-Shavit R., Ishai-Michaeli R., Bashkin P., Fuks Z. Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism?. Trends Biochem. Sci. 1991, 16:268-271.
88. Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R., Ishai-Michaeli R., Bitan M., Pappo O., Peretz T., Michal I., Spector L., Pecker I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 1999, 5:793-802.
89. Vlodavsky I., Ilan N., Naggi A., Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr. Pharm. Des. 2007, 13:2057-2073.
90. Vlodavsky I., Beckhove P., Lerner I., Pisano C., Meirovitz A., Ilan N., Elkin M. Significance of heparanase in cancer and inflammation. Cancer Microenviron. 2012, 5:115-132.
91. Vreys V., David G. Mammalian heparanase: what is the message?. J. Cell. Mol. Med. 2007, 11:427-452.
92. Wang F., Kim M.S., Puthanveetil P., Kewalramani G., Deppe S., Ghosh S., Abrahani A., Rodrigues B. Endothelial heparanase secretion after acute hypoinsulinemia is regulated by glucose and fatty acid. Am. J. Physiol. 2009, 296:H1108-H1116.
93. Wang F., Wang Y., Zhang D., Puthanveetil P., Johnson J.D., Rodrigues B. Fatty acid-induced nuclear translocation of heparanase uncouples glucose metabolism in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2012, 32:406-414.
94. Wang Y., Zhang D., Chiu A.P., Wan A., Neumaier K., Vlodavsky I., Rodrigues B. Endothelial heparanase regulates heart metabolism by stimulating lipoprotein lipase secretion from cardiomyocytes. Arterioscler Thromb. Vasc. Biol. 2013, Mar 7.
95. Wight T.N., Merrilees M.J. Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ. Res. 2004, 94:1158-1167.
96. Yang Y., MacLeod V., Dai Y., Khotskaya-Sample Y., Shriver Z., Venkataraman G., Sasisekharan R., Naggi A., Torri G., Casu B., Vlodavsky I., Suva L.J., Epstein J., Yaccoby S., Shaughnessy J.D., Barlogie B., Sanderson R.D. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007, 110:2041-2048.
97. Yang Y., Macleod V., Miao H.Q., Theus A., Zhan F., Shaughnessy J.D., Sawyer J., Li J.P., Zcharia E., Vlodavsky I., Sanderson R.D. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J. Biol. Chem. 2007, 282:13326-13333.
98. Yang Y., Ren Y., Ramani V.C., Nan L., Suva L.J., Sanderson R.D. Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. Cancer Res. 2010, 70:8329-8338.
99. Zcharia E., Jia J., Zhang X., Baraz L., Lindahl U., Peretz T., Vlodavsky I., Li J.P. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One 2009, 4:e5181.
100. Zetser A., Bashenko Y., Edovitsky E., Levy-Adam F., Vlodavsky I., Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res. 2006, 66:1455-1463.
101. Zhang L., Sullivan P.S., Goodman J.C., Gunaratne P.H., Marchetti D. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res. 2011, 71:645-654.
102. Zhou H., Roy S., Cochran E., Zouaoui R., Chu C.L., Duffner J., Zhao G., Smith S., Galcheva-Gargova Z., Karlgren J., Dussault N., Kwan R.Y., Moy E., Barnes M., Long A., Honan C., Qi Y.W., Shriver Z., Ganguly T., Schultes B., Venkataraman G., Kishimoto T.K. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One 2011, 6:e21106.
103. Ziolkowski A.F., Popp S.K., Freeman C., Parish C.R., Simeonovic C.J. Heparan sulfate and heparanase play key roles in mouse beta cell survival and autoimmune diabetes. J. Clin. Invest. 2012, 122:132-141.